Genetic Signatures (ASX:GSS) said that its Chief Executive Officer, Allison Rossiter, informed the board that she will be leaving the firm in late February 2026 to take on a role with a global pharmaceutical firm, according to a Monday Australian bourse filing.
Jenny Harry and Anne Lockwood will support the management team during the transition.
Its shares fell 9% in recent trading on Monday.